- Home
- CCM vs KZR Comparison
CCM vs KZR Comparison
Compare CCM & KZR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCM
- KZR
- Stock Information
- Founded
- CCM 1997
- KZR 2015
- Country
- CCM China
- KZR United States
- Employees
- CCM N/A
- KZR N/A
- Industry
- CCM Medical/Nursing Services
- KZR Biotechnology: Pharmaceutical Preparations
- Sector
- CCM Health Care
- KZR Health Care
- Exchange
- CCM Nasdaq
- KZR Nasdaq
- Market Cap
- CCM 33.3M
- KZR 29.7M
- IPO Year
- CCM 2009
- KZR 2018
- Fundamental
- Price
- CCM $5.71
- KZR $3.91
- Analyst Decision
- CCM
- KZR Hold
- Analyst Count
- CCM 0
- KZR 2
- Target Price
- CCM N/A
- KZR $9.00
- AVG Volume (30 Days)
- CCM 1.9K
- KZR 34.3K
- Earning Date
- CCM 09-22-2025
- KZR 11-11-2025
- Dividend Yield
- CCM N/A
- KZR N/A
- EPS Growth
- CCM N/A
- KZR N/A
- EPS
- CCM N/A
- KZR N/A
- Revenue
- CCM $52,603,198.00
- KZR N/A
- Revenue This Year
- CCM N/A
- KZR N/A
- Revenue Next Year
- CCM N/A
- KZR N/A
- P/E Ratio
- CCM N/A
- KZR N/A
- Revenue Growth
- CCM N/A
- KZR N/A
- 52 Week Low
- CCM $3.80
- KZR $3.62
- 52 Week High
- CCM $10.77
- KZR $9.18
- Technical
- Relative Strength Index (RSI)
- CCM 57.10
- KZR 43.94
- Support Level
- CCM $5.46
- KZR $3.76
- Resistance Level
- CCM $5.99
- KZR $4.09
- Average True Range (ATR)
- CCM 0.13
- KZR 0.14
- MACD
- CCM 0.05
- KZR 0.01
- Stochastic Oscillator
- CCM 68.54
- KZR 38.46
About CCM Concord Medical Services Holdings Limited
Concord Medical Services Holdings Ltd operates radiotherapy and diagnostic imaging centers in China. The company is involved in the leasing of radiotherapy and diagnostic imaging equipment, provision of management services to hospitals, medicine sales, and provision of premium cancer and proton treatment services. The company has two operating segments, including network and hospital. Its network includes radiotherapy centers, diagnostic imaging centers, and centers providing other treatment and diagnostic services.
About KZR Kezar Life Sciences Inc.
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.